KRAS mutations were detected in 62 (37%), BRAF mutations in 13 (8%) and PIK3CA mutations in 26 (15%, 18 in exon 9 and 8 in exon 20) primary tumours, respectively. This evidence concerns the gene KRAS and neoplasm.